PDCD1 and cancer: At present, it is widely accepted that the antitumor mechanism of PD-1/PD-L1 blockade immunotherapy involves the rejuvenation of T cells, but recent studies have demonstrated that there is a complicated relationship between macrophages and the PD-1/PD-L1 pathway during the progression of cancer.